TK1 and breast carcinoma: Furthermore, anti-TK1 antibodies induced cytolysis of lung and breast cancer cells by effector cells demonstrating the potential to be used as immunotargeting agents to eliminate high TK1 expressing tumor cells in cancer therapy [87].